Opyl's strategic partnership announcement

Opyl (ASX:OPL) has signed a Service Level Agreement with Southern Clinical Development Consulting (Southern CDC). This collaboration allows Southern CDC to leverage Opyl's TrialKey platform for improving clinical trial support. The agreement is initially set for six months, with potential extensions.

Opyl's collaborative move in clinical trials

Opyl Limited's agreement with Southern CDC marks a significant step in its strategy to enhance clinical trial processes using AI technology. The TrialKey platform will aid in designing and planning trials more effectively, offering predictive modeling and competitor analysis. This partnership aligns with Opyl's goal of expanding its influence in global clinical trial management. The collaboration is anticipated to improve patient access to innovative treatments, reflecting Opyl's commitment to healthcare innovation and growth.

Executive insights on Opyl's new partnership

This partnership is a strategic step forward for Opyl, aiming to harness the global potential of the TrialKey platform,' said Saurabh Jain, Executive Chairman of Opyl. 'TrialKey will enable us to refine trial designs, optimize site selections, and craft effective recruitment strategies,' added Dr. Khalid Abubaker, COO of Southern CDC.